[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1988

Anti-Ro (SSA) and Anti-La (SSB) Antibodies in Lupus Erythematosus and in Sjögren's Syndrome

Author Affiliations

Department of Dermatology University of Colorado School of Medicine 4200 E Ninth Ave Denver, CO 80262

Arch Dermatol. 1988;124(1):61-62. doi:10.1001/archderm.1988.01670010025016
Abstract

Lupus erythematosus and Sjögren's syndrome have long been characterized as autoimmune diseases. However, the meaning behind the word autoimmune was and is often vague. Does "autoimmune" in the case of lupus erythematosus and Sjögren's syndrome imply autoantibody-mediated? If so, which autoantibodies are important? At this time, the pathogeneses of lupus erythematosus and Sjögren's syndrome have not been elucidated and it is not possible to answer these questions. Nevertheless, there is, at least in lupus erythematosus, a reasonably large body of experimental evidence supporting the possibility that autoantibody production is the primary abnormality.1 In New Zealand black/New Zealand white mice, a strain that spontaneously develops lupus erythematosus with glomerulonephritis, autoantibodies are the first observable abnormality. Detectable levels of antibodies to DNA precede the first signs of renal disease by a few weeks.2 Further, in many murine models of lupus erythematosus, the addition of a gene called xid results in

First Page Preview View Large
First page PDF preview
First page PDF preview
×